RT Journal Article
SR Electronic
T1 Evolution of long-term vaccine induced and hybrid immunity in healthcare workers after different COVID-19 vaccination regimens: a longitudinal observational cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.06.06.22275865
DO 10.1101/2022.06.06.22275865
A1 Moore, Shona C.
A1 Kronsteiner, Barbara
A1 Longet, Stephanie
A1 Adele, Sandra
A1 Deeks, Alexandra S.
A1 Liu, Chang
A1 Dejnirattisai, Wanwisa
A1 Reyes, Laura Silva
A1 Meardon, Naomi
A1 Faustini, Sian
A1 Al-Taei, Saly
A1 Tipton, Tom
A1 Hering, Luisa M
A1 Angyal, Adrienn
A1 Brown, Rebecca
A1 Nicols, Alexander R
A1 Dobson, Susan L
A1 Supasa, Piyada
A1 Tuekprakhon, Aekkachai
A1 Cross, Andrew
A1 Tyerman, Jessica K
A1 Hornsby, Hailey
A1 Grouneva, Irina
A1 Plowright, Megan
A1 Zhang, Peijun
A1 Newman, Thomas A.H.
A1 Nell, Jeremy M.
A1 Abraham, Priyanka
A1 Ali, Mohammad
A1 Malone, Tom
A1 Neale, Isabel
A1 Phillips, Eloise
A1 Wilson, Joseph D.
A1 Murray, Sam M.
A1 Zewdie, Martha
A1 Shields, Adrian
A1 Horner, Emily C.
A1 Booth, Lucy H.
A1 Stafford, Lizzie
A1 Bibi, Sagida
A1 Wootton, Daniel G.
A1 Mentzer, Alexander J.
A1 Conlon, Christopher P.
A1 Jeffery, Katie
A1 Matthews, Philippa C.
A1 Pollard, Andrew J.
A1 Brown, Anthony
A1 Rowland-Jones, Sarah L.
A1 Mongkolsapaya, Juthathip
A1 Payne, Rebecca P.
A1 Dold, Christina
A1 Lambe, Teresa
A1 Thaventhiran, James E.D.
A1 Screaton, Gavin
A1 Barnes, Eleanor
A1 Hopkins, Susan
A1 Hall, Victoria
A1 Duncan, Christopher JA
A1 Richter, Alex
A1 Carroll, Miles
A1 de Silva, Thushan I.
A1 Klenerman, Paul
A1 Dunachie, Susanna
A1 Turtle, Lance
A1 ,
YR 2022
UL http://medrxiv.org/content/early/2022/12/21/2022.06.06.22275865.abstract
AB Both infection and vaccination, alone or in combination, generate antibody and T cell responses against SARS-CoV-2. However, the maintenance of such responses – and hence protection from disease – requires careful characterisation. In a large prospective study of UK healthcare workers (Protective immunity from T cells in Healthcare workers (PITCH), within the larger SARS-CoV-2 immunity & reinfection evaluation (SIREN) study) we previously observed that prior infection impacted strongly on subsequent cellular and humoral immunity induced after long and short dosing intervals of BNT162b2 (Pfizer/BioNTech) vaccination. Here, we report longer follow up of 684 HCWs in this cohort over 6-9 months following two doses of BNT162b2 or AZD1222 (Oxford/AstraZeneca) vaccination and up to 6 months following a subsequent mRNA booster vaccination. We make three observations: Firstly, the dynamics of humoral and cellular responses differ; binding and neutralising antibodies declined whereas T and memory B cell responses were maintained after the second vaccine dose. Secondly, vaccine boosting restored IgG levels, broadened neutralising activity against variants of concern including omicron BA.1, BA.2 and BA.5, and boosted T cell responses above the 6 month level post dose 2. Thirdly, prior infection maintained its impact driving larger as well as broader T cell responses compared with never-infected people – a feature maintained until 6 months after the third dose. In conclusion, broadly cross-reactive T cell responses are well maintained over time – especially in those with combined vaccine and infection-induced immunity (“hybrid” immunity) – and may contribute to continued protection against severe disease.Competing Interest StatementThe views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, the Department of Health and Social Care or Public Health England or the US Food and Drug Administration. S.J.D. is a Scientific Advisor to the Scottish Parliament on COVID-19 for which she receives a fee. A.J.P. is Chair of UK Dept. Health and Social Care’s (DHSC) Joint Committee on Vaccination & Immunisation (JCVI), but does not participate in policy decisions on COVID-19 vaccines. He was previously a member of the WHO’s SAGE. The views expressed in this article do not necessarily represent the views of DHSC, JCVI, or WHO. AJP is chief investigator on clinical trials of Oxford University’s COVID-19 vaccine funded by NIHR. Oxford University has entered a joint COVID-19 vaccine development partnership with AstraZeneca. G.S. sits on the GSK Vaccines Scientific Advisory Board and is a founder member of RQ Biotechnology. LT declares a fee from Eisai ltd for speaking at the Multi-tumour first thoughts meeting on 4th March 2021. Clinical Protocols https://www.pitch-study.org Funding StatementThis work was funded by the UK Department of Health and Social Care as part of the PITCH (Protective Immunity from T cells to Covid-19 in Health workers) Consortium, UKRI as part of ‘Investigation of proven vaccine breakthrough by SARS-CoV-2 variants in established UK healthcare worker cohorts: SIREN consortium & PITCH Plus Pathway’ MR/W02067X/1, with contributions from UKRI/NIHR through the UK Coronavirus Immunology Consortium (UK-CIC), the Huo Family Foundation and The National Institute for Health Research (UKRIDHSC COVID-19 Rapid Response Rolling Call, Grant Reference Number COV19-RECPLAS). E.B. and P.K. are NIHR Senior Investigators and P.K. is funded by WT109965MA. S.J.D. is funded by an NIHR Global Research Professorship (NIHR300791). T.dS is funded by a Wellcome Trust Intermediate Clinical Fellowship (110058/Z/15/Z). RPP is funded by a Career Re-entry Fellowship (204721/Z/16/Z). C.J.A.D. is funded by a Wellcome Clinical Research Career Development Fellowship (211153/Z/18/Z). J.M. and G.S. are funded by the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Science (CIFMS), China (grant number: 2018-I2M-2-002), Schmidt Futures, the Red Avenue Foundation and the Oak Foundation. The Wellcome Centre for Human Genetics is supported by the Wellcome Trust (grant 090532/Z/09/Z). P.C.M. is funded by Wellcome (110110z/15/Z), the Francis Crick Institute, and the University College London Hospital NIHR Biomedical Research Centre. J.E.D.T. is supported by the Medical Research Council (MR/W020564/1) and (MC_UU_0025/12). L.T. is supported by the Wellcome Trust (grant number 205228/Z/16/Z) and the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Emerging and Zoonotic Infections (NIHR200907) at University of Liverpool in partnership with UK Health Security Agency (UKHSA), in collaboration with Liverpool School of Tropical Medicine and the University of Oxford. D.G.W. is supported by an NIHR Advanced Fellowship in Liverpool. M.C., S.L., L.T., and T.T. are supported by U.S. Food and Drug Administration Medical Countermeasures Initiative contract 75F40120C00085. The Sheffield Teaching Hospitals Observational Study of Patients with Pulmonary Hypertension, Cardiovascular and other Respiratory Diseases (STH-ObS) was supported by the British Heart Foundation (PG/11/116/29288). The STH-ObS Chief Investigator Allan Laurie is supported by a British Heart Foundation Senior Basic Science Research fellowship (FS/18/52/33808). We gratefully acknowledge financial support from the UK Department of Health and Social Care via the Sheffield NIHR Clinical Research Facility award to the Sheffield Teaching Hospitals Foundation NHS Trust. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:PITCH is a sub-study of the SIREN study, which was approved by the Berkshire Research Ethics Committee, Health Research 250 Authority (IRAS ID 284460, REC reference 20/SC/0230), with PITCH recognised as a sub-study on 2 December 2020. SIREN is registered with ISRCTN (Trial ID:252 ISRCTN11041050). Some participants were recruited under aligned study protocols. In Birmingham participants were recruited under the Determining the immune response to SARS-CoV-2 infection in convalescent health care workers (COCO) study (IRAS ID: 282525). In Liverpool some participants were recruited under the ‘Human immune responses to acute virus infections’ Study (16/NW/0170), approved by North West - Liverpool Central Research Ethics Committee on 8 March 2016, and amended on 14th September 2020 and 4th May 2021. In Oxford, participants were recruited under the GI Biobank Study 16/YH/0247, approved by the research ethics committee (REC) at Yorkshire & The Humber - Sheffield Research Ethics Committee on 29 July 2016, which has been amended for this purpose on 8 June 2020. In Sheffield, participants were recruited under the Observational Biobanking study STHObs (18/YH/0441), which was amended for this study on 10 September 2020. We also included some participants from Cambridge from a study approved by the National Research Ethics Committee and Health Research Authority (East of England — Cambridge Research Ethics Committee (SCORPIO study, SARS-CoV-2 vaccination response in obesity amendment of ‘NIHR BioResource’ 17/EE/0025). The study was conducted in compliance with all relevant ethical regulations for work with human participants, and according to the principles of the Declaration of Helsinki (2008) and the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines. Written informed consent was obtained for all participants enrolled in the study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors